Atrion in $24.5 million deal for Quest cardiovascular lines
This article was originally published in Clinica
Atrion has agreed to buy Quest Medical's cardiovascular and intravenous fluid delivery product lines for $24.5 million in cash. Atrion will also get Quest's 27 patents relating to the products and will lease Quest's factory in Texas where the products are made - with an option to buy the plant for a further $6.5 million.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.